How Does Ebglyss Work?
Ebglyss (lebrikizumab-lbkz) is a humanized monoclonal antibody that selectively binds to soluble interleukin-13 (IL-13). This binding prevents IL-13 from interacting with the IL-4 receptor alpha/IL-13 receptor alpha 1 heterodimer (IL-4Rα/IL-13Rα1), blocking IL-13 signaling through this pathway.[1][2]
Role of IL-13 in Atopic Dermatitis
IL-13 drives type 2 inflammation in atopic dermatitis by promoting Th2 cell differentiation, IgE class switching in B cells, chemokine production, and skin barrier dysfunction via keratinocyte effects. Ebglyss targets this cytokine specifically, reducing inflammation without broadly inhibiting IL-4 signaling.[1][3]
How It Differs from Dupixent
Unlike dupilumab, which blocks both IL-4 and IL-13 by targeting IL-4Rα, Ebglyss spares IL-4 signaling while neutralizing only IL-13. This selectivity may lead to fewer side effects like conjunctivitis in some patients.[2][4]
Clinical Evidence on Mechanism
Phase 3 trials (ADvocate1, ADvocate2, ADjoin) showed Ebglyss reduces IL-13-driven biomarkers like CCL17 (TARC) and IgE, correlating with EASI score improvements. It achieves steady-state exposure by week 16 after initial loading doses.[1][5]
Who Makes Ebglyss and Approval Details
Eli Lilly manufactures Ebglyss, approved by the FDA in September 2024 for moderate-to-severe atopic dermatitis in adults and children 12+ weighing at least 40 kg, after prior treatments fail.[1][6]
[1]: FDA Label for Ebglyss
[2]: Lilly Press Release on Ebglyss Approval
[3]: New England Journal of Medicine - Lebrikizumab Trials
[4]: Journal of Allergy and Clinical Immunology - IL-13 Specificity
[5]: ADvocate Study Results
[6]: Drugs@FDA - Ebglyss Approval